Abstract:In the context of inflammation, T cell activation occurs by the concerted signals of the T cell receptor (TCR), co-stimulatory receptors ligation, and a pro-inflammatory cytokine microenvironment. Fine-tuning these signals is crucial to maintain T cell homeostasis and prevent self-reactivity while offering protection against infectious diseases and cancer. Recent developments in understanding the complex crosstalk between the molecular events controlling T cell activation and the balancing regulatory cues offer novel approaches for the development of T cell-based immunotherapies. Among the complex regulatory processes, the balance between protein tyrosine kinases (PTK) and the protein tyrosine phosphatases (PTPs) controls the transcriptional and metabolic programs that determine T cell function, fate decision, and activation. In those, PTPs are de facto regulators of signaling in T cells acting for the most part as negative regulators of the canonical TCR pathway, costimulatory molecules such as CD28, and cytokine signaling. In this review, we examine the function of two close PTP homologs, PTP1B (PTPN1) and T-cell PTP (TCPTP; PTPN2), which have been recently identified as promising candidates for novel T-cell immunotherapeutic approaches. Herein, we focus on recent studies that examine the known contributions of these PTPs to T-cell development, homeostasis, and T-cell-mediated immunity. Additionally, we describe the signaling networks that underscored the ability of TCPTP and PTP1B, either individually and notably in combination, to attenuate TCR and JAK/STAT signals affecting T cell responses. Thus, we anticipate that uncovering the role of these two PTPs in T-cell biology may lead to new treatment strategies in the field of cancer immunotherapy. This review concludes by exploring the impacts and risks that pharmacological inhibition of these PTP enzymes offers as a therapeutic approach in T-cell-based immunotherapies.

The PI3K/AKT signaling pathway in regulatory T‐cell development, stability, and function

Major Physiological Signaling Pathways in the Regulation of Cell Proliferation and Survival

T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR

The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications

The PTEN–PI3K Axis in Cancer

PI3K Isoforms in CD8+ T Cell Development and Function

Inactivation of the Enzyme GSK3α by the Kinase IKKi Promotes AKT-mTOR Signaling Pathway that Mediates Interleukin-1-Induced Th17 Cell Maintenance

Glycogen synthase kinase-3 is essential for Treg development and function

Control of regulatory T (Treg) cell function by protein kinase C-eta (PKCη): A novel target for cancer immunotherapy

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

PI3K/AKT signaling pathway and cancer: an updated review

A PI3Kδ-Foxo1-FasL signaling amplification loop rewires CD4+ T helper cell signaling, differentiation and epigenetic remodeling

The PTEN–PI3K pathway: of feedbacks and cross-talks

Pim-2 Kinase Influences Regulatory T Cell Function and Stability by Mediating Foxp3 Protein N-terminal Phosphorylation

Advances in the Researches on the Biological Activities and Inhibitors of Phosphatidylinositol 3-Kinase.

The PI3K/AKT signaling pathway in cancer: Molecular mechanisms and possible therapeutic interventions

Interleukin-2-inducible T-cell kinase (Itk) signaling regulates potent noncanonical regulatory T cells

Signaling interplay between transforming growth factor-β receptor and PI3K/AKT pathways in cancer.

PI3K signaling-regulated metabolic reprogramming: From mechanism to application

Immunotherapeutic implications of negative regulation by protein tyrosine phosphatases in T cells: the emerging cases of PTP1B and TCPTP

The phosphatidylinositol 3-Kinase–AKT pathway in human cancer